# nature portfolio

Corresponding author(s):	Michael Lanzer
Last updated by author(s):	February 21st, 2025

## **Reporting Summary**

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency

in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested
A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted Give <i>P</i> values as exact values whenever suitable.
For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
Estimates of effect sizes (e.g. Cohen's $d$ , Pearson's $r$ ), indicating how they were calculated
Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
Software and code
Policy information about <u>availability of computer code</u>
Data collection Zeiss Airyscan LSM900 microscope in super-resolution mode
Data analysis Cellpose, ilastik, codes are available at: https://github.com/sciai-lab/CP_RBC_Pfalciparum
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

#### Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

All data supporting the findings of this study are available within the article and the attached source data file. Additionally, the images and segmentation underpinning this study are available at the zenodo public repository under https://doi.org/10.5281/zenodo.14281268.

Research inv	olving human participants, their data, or biological material
·	bout studies with

Timing

Data exclusions

Non-participation

Randomization

All studies must disclose on	these points even when the disclosure is negative.
Study description	
Research sample	
Sampling strategy	
Data collection	
Timing and spatial scale	
Data exclusions	
Reproducibility	
Randomization	
Blinding	
Did the study involve field  Field work, collect	
,	'
Field conditions	
Location	
Access & import/export	
Disturbance	
We require information from a	r specific materials, systems and methods  uthors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, yant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
system of method listed is rele-	
Materials & experime	<del></del>
n/a Involved in the study  Antibodies	n/a   Involved in the study  ☑ ChIP-seq
Eukaryotic cell lines	Flow cytometry
Palaeontology and a	
Animals and other or	ganisms
Dual use research of	concern
✓ Plants	
Antibodies	
Antibodies used	KAHRP antibodies
Validation	Sanchez et al. Mol Microbiol 117, 274-292, https://doi.org/10.1111/mmi.14811 (2022)

Eukaryotic cell lines	
Policy information about <u>cell lin</u>	nes and Sex and Gender in Research
Cell line source(s)	P. falciparum FCR3
Authentication	was confirmed by microsatelites
Mycoplasma contamination	was tested prior to the study
Commonly misidentified lines (See <u>ICLAC</u> register)	not applicable
Palaeontology and A	archaeology
Specimen provenance	
Specimen deposition	
Dating methods	
Tick this box to confirm th	at the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight	
Note that full information on the ap	proval of the study protocol must also be provided in the manuscript.
Animals and other re	esearch organisms
Policy information about <u>studie</u> Research	s involving animals; ARRIVE guidelines recommended for reporting animal research, and <u>Sex and Gender in</u>
Laboratory animals	
Wild animals	
Reporting on sex	
Field-collected samples	
Ethics oversight	
Note that full information on the ap	proval of the study protocol must also be provided in the manuscript.
Clinical data	
Policy information about <u>clinica</u> All manuscripts should comply with	l studies the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.
Clinical trial registration	
Study protocol	
Data collection	
Outcomes	

### Dual use research of concern

Policy information about <u>dual use research of concern</u>

#### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

No Yes  Public health  National security  Crops and/or livestor  Ecosystems  Any other significan	
Experiments of concern	n
Does the work involve any	y of these experiments of concern:
Confer resistance to Enhance the viruler Increase transmissil Alter the host range Enable evasion of d Enable the weaponi	
—,—	
Plants	
Seed stocks	
Novel plant genotypes	
Authentication	
ChIP-seq	
Confirm that you have	and final processed data have been deposited in a public database such as <u>GEO</u> . deposited or provided access to graph files (e.g. BED files) for the called peaks.
Data access links May remain private before publica	ation.
Files in database submission	on (
Genome browser session (e.g. <u>UCSC</u> )	
Methodology	
Replicates	
Sequencing depth	
Antibodies	
Peak calling parameters	

Data quality

Software	
Flow Cytometry	
Plots	
Confirm that:	
The axis labels state the	marker and fluorochrome used (e.g. CD4-FITC).
The axis scales are clearl	y visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
All plots are contour plot	ts with outliers or pseudocolor plots.
A numerical value for nu	mber of cells or percentage (with statistics) is provided.
Methodology	
Sample preparation	
Instrument	
Software	
Cell population abundance	
Gating strategy	
Tick this box to confirm t	that a figure exemplifying the gating strategy is provided in the Supplementary Information.
Magnetic resonanc	e imaging
Experimental design	
Design type	
Design specifications	
Behavioral performance me	asures
Imaging type(s)	
Field strength	
Sequence & imaging parame	eters
Area of acquisition	
Diffusion MRI Us	ed Not used
Preprocessing	
Preprocessing software	
Normalization	
Normalization template	
Noise and artifact removal	
Volume censoring	
Statistical modeling & in	ference
Model type and settings	
Effect(s) tested	

nature portfolio
reporting su
summary

$\rightarrow$	
≂	
_	
۶	
Ķ	
	١

Specify type of analysis: Whole brain ROI-based Both	
Statistic type for inference	
(See Eklund et al. 2016)	
Correction	
Models & analysis	
n/a   Involved in the study	
Functional and/or effective connectivity	
Graph analysis	
Multivariate modeling or predictive analysis	
Functional and/or effective connectivity	
Graph analysis	
Multivariate modeling and predictive analysis	